Posted On: 09/30/2014 9:01:30 PM
Post# of 273351
Celgene Corp (CELG) 94.78 $CELG
Final Glance: Biotechnology companies
AP - 2 hrs 56 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Tue Sep 30, 12:20PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Sep 30, 9:40AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:30PM CDT
Shares of Agios Pharmaceuticals (AGIO) jumped 19.3% on the announcement that it will present data on AG-120 earlier than expected.
'Fast Money' Recap: Why Volatility Might Be a Good Thing
at The Street - Sat Sep 27, 4:00AM CDT
The trading panel discussed how to trade Yahoo!, Nike and biotech companies.
Agios drug data boosts stock
at Investor's Business Daily - Fri Sep 26, 5:52PM CDT
Biotech startup Agios Pharmaceuticals (AGIO) got a 19.3% boost to a new high of 63.76 after the company said that it would release key clinical trial data from its phase 1 study of blood cancer treatment AG-120 earlier than anticipated. It's...
Agios' Early Drug-Trial Report Cheers Wall Street
at Investor's Business Daily - Fri Sep 26, 12:21PM CDT
Shares of biotech startup Agios Pharmaceuticals (AGIO) soared 20% in the stock market today to a new high above 64 after it said it would report data from a key clinical trial earlier than expected, leading analysts to believe the news will be good....
Jim Cramer's Stop Trading: Does Agios Pharmaceuticals Have a Monumental Cancer Treatment?
at The Street - Fri Sep 26, 10:58AM CDT
TheStreet's Jim Cramer suggests that the only reason Agios Pharmaceuticals would present its cancer treatment data so early is if the company believes it can be monumental in the future.
Technology Stocks Slide But Other Sectors Hold Up Better
at Investor's Business Daily - Thu Sep 25, 5:55PM CDT
A harsh sell-off in the market Thursday did not spare many stocks in Your Weekly Review. Nearly every stock on the screen closed lower, and the selling affected certain sectors more than others. However, few leaders triggered outright sell signals....
Stocks Get Hit Hard; GoPro, Skechers Buck Weakness
at Investor's Business Daily - Thu Sep 25, 3:23PM CDT
Stocks suffered their biggest losses in nearly two months Thursday amid mixed data on weekly jobless claims and durable goods. Hurt by a near 4% drop in Apple (AAPL), the Nasdaq tumbled 1.9%. The S&P 500 lost 1.6%. Both indexes breached support at...
Apple Fuels Tech Sell-Off; Valeant Bucks The Trend
at Investor's Business Daily - Thu Sep 25, 10:34AM CDT
Major averages were sharply lower two hours into Thursday's session. The Nasdaq slumped 1.7% as Apple cast a pall on the tech sector. The Dow Jones industrial average and S&P 500 lost 1.2% each, and small caps took another hit as the Russell 2000...
The Best Biotech Stock for Your Growth Portfolio
Motley Fool Staff - Motley Fool - Thu Sep 25, 7:45AM CDT
For those willing to endure the inevitable price roller coaster, there's tremendous opportunity in hyper-growth biotech stocks. But you have to pick the best stocks if you're going to generate market-beating returns. So we asked each of our analysts...
'Fast Money' Recap: What Market? The Focus Remains on Apple
at The Street - Thu Sep 25, 4:00AM CDT
The trading panel discussed how low the market can go and whether biotech stocks can continue to move higher.
Jim Cramer's 'Mad Money' Recap: Why You Can't Get Too Negative in This Market
at The Street - Wed Sep 24, 7:24PM CDT
Investors always need to be prepared for when common sense returns to the market, Cramer says.
Celgene's Otezla Label Expanded to Include Plaque Psoriasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:30PM CDT
Celgene's (CELG) Otezla gained FDA approval for plaque psoriasis.
Final Glance: Biotechnology companies
AP - 2 hrs 56 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Tue Sep 30, 12:20PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Sep 30, 9:40AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:30PM CDT
Shares of Agios Pharmaceuticals (AGIO) jumped 19.3% on the announcement that it will present data on AG-120 earlier than expected.
'Fast Money' Recap: Why Volatility Might Be a Good Thing
at The Street - Sat Sep 27, 4:00AM CDT
The trading panel discussed how to trade Yahoo!, Nike and biotech companies.
Agios drug data boosts stock
at Investor's Business Daily - Fri Sep 26, 5:52PM CDT
Biotech startup Agios Pharmaceuticals (AGIO) got a 19.3% boost to a new high of 63.76 after the company said that it would release key clinical trial data from its phase 1 study of blood cancer treatment AG-120 earlier than anticipated. It's...
Agios' Early Drug-Trial Report Cheers Wall Street
at Investor's Business Daily - Fri Sep 26, 12:21PM CDT
Shares of biotech startup Agios Pharmaceuticals (AGIO) soared 20% in the stock market today to a new high above 64 after it said it would report data from a key clinical trial earlier than expected, leading analysts to believe the news will be good....
Jim Cramer's Stop Trading: Does Agios Pharmaceuticals Have a Monumental Cancer Treatment?
at The Street - Fri Sep 26, 10:58AM CDT
TheStreet's Jim Cramer suggests that the only reason Agios Pharmaceuticals would present its cancer treatment data so early is if the company believes it can be monumental in the future.
Technology Stocks Slide But Other Sectors Hold Up Better
at Investor's Business Daily - Thu Sep 25, 5:55PM CDT
A harsh sell-off in the market Thursday did not spare many stocks in Your Weekly Review. Nearly every stock on the screen closed lower, and the selling affected certain sectors more than others. However, few leaders triggered outright sell signals....
Stocks Get Hit Hard; GoPro, Skechers Buck Weakness
at Investor's Business Daily - Thu Sep 25, 3:23PM CDT
Stocks suffered their biggest losses in nearly two months Thursday amid mixed data on weekly jobless claims and durable goods. Hurt by a near 4% drop in Apple (AAPL), the Nasdaq tumbled 1.9%. The S&P 500 lost 1.6%. Both indexes breached support at...
Apple Fuels Tech Sell-Off; Valeant Bucks The Trend
at Investor's Business Daily - Thu Sep 25, 10:34AM CDT
Major averages were sharply lower two hours into Thursday's session. The Nasdaq slumped 1.7% as Apple cast a pall on the tech sector. The Dow Jones industrial average and S&P 500 lost 1.2% each, and small caps took another hit as the Russell 2000...
The Best Biotech Stock for Your Growth Portfolio
Motley Fool Staff - Motley Fool - Thu Sep 25, 7:45AM CDT
For those willing to endure the inevitable price roller coaster, there's tremendous opportunity in hyper-growth biotech stocks. But you have to pick the best stocks if you're going to generate market-beating returns. So we asked each of our analysts...
'Fast Money' Recap: What Market? The Focus Remains on Apple
at The Street - Thu Sep 25, 4:00AM CDT
The trading panel discussed how low the market can go and whether biotech stocks can continue to move higher.
Jim Cramer's 'Mad Money' Recap: Why You Can't Get Too Negative in This Market
at The Street - Wed Sep 24, 7:24PM CDT
Investors always need to be prepared for when common sense returns to the market, Cramer says.
Celgene's Otezla Label Expanded to Include Plaque Psoriasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:30PM CDT
Celgene's (CELG) Otezla gained FDA approval for plaque psoriasis.
(0)
(0)
